Company ProfilePremium

Hyloris Pharmaceuticals SA

Company Profile Analysis

Ticker: HYL.BR

ESOMAR 23 Corporate BadgeISO Certifications Badge
Hyloris Pharmaceuticals SA - Company showcase

Year Founded & Workforce

2012

54 Employees

Hyloris Pharmaceuticals SA logo

Hyloris Pharmaceuticals SA Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Hyloris Pharmaceuticals SA Overview

Hyloris is a Liège-based specialty pharmaceutical group that creates "value-added medicines" by reformulating, repurposing and re-registering established molecules, primarily via the US FDA 505(b)(2) pathway and its European equivalents, and increasingly through selected, risk-mitigated new chemical entities. Its model is asset-light: development is outsourced to CMOs and CROs, and commercialisation is almost entirely partnered, with Hyloris capturing royalties, profit shares and milestones. Four products are now commercialised through partners — Maxigesic® IV (Combogesic® IV in the US), Sotalol IV, Podofilox Gel and Tranexamic Acid IV RTU — and the pipeline exceeds 30 products and candidates organised into "Core Drivers", "Mavericks" and "Promising Seeds". The company targets a development cost below EUR 7M per product over up to seven years. Revenue remains small (EUR 7.2M in FY2025) and loss-making, governance has been under regulatory scrutiny since 2024, and liquidity is tight (EUR 8.7M cash at 30 June 2026), making partnering execution the central value driver.


Company's own description

In its FY2025 and H1 2026 regulated releases, Hyloris describes itself as a specialty pharma group focused on reinventing and optimising existing medications through reformulation and repurposing to address healthcare needs for patients, healthcare professionals and payers. It emphasises leveraging established regulatory pathways (FDA 505(b)(2) and equivalents) for molecules whose safety and efficacy are already established, which it argues reduces clinical and regulatory burden, shortens timelines and lowers cost and risk. Since 2026 its boilerplate has added "smart NCE developments" to the description, reflecting in-licensed new chemical entities such as HY-094 (IV iron), Suramin IV and Methanobactin (HY-106). The company also states a targeted time-to-market of seven years at an average cost of EUR 7M per product (non-inflation adjusted) (H1 2026 release).

Business model

Hyloris operates a hub-and-partner model:

Sourcing: products are originated internally or in-licensed from academic institutions, small biotechs and development partners (e.g., AFT Pharmaceuticals, API, Vaneltix, Pleco Therapeutics, Purna/FHP BV, RedHill Biopharma, ArborMed, Wake Forest University, Kuvatris Therapeutics).

Development: formulation and analytical work partly in-house (in-house lab at LégiaPark built 2022–2023), with manufacturing at CMOs/CDMOs and clinical studies run via CROs.

Commercialisation: almost entirely out-licensed to regional partners (Hikma in the US for Maxigesic IV via AFT; AltaThera for Sotalol IV; Padagis for Podofilox Gel; Avenacy for TXA RTU US; Orion in Europe for TXA RTU and Pantoprazole IV RTU; Rosemont for US Valacyclovir and Atomoxetine oral liquids; numerous others). The company's stated strategic objective (FY2024 release) is to capture a significant share of net product margin realised by partners, preferring in-market sales or profit participation over upfront fees, and partnering near regulatory submission.

US cardiovascular strategy: historically, Hyloris planned to build its own US hospital sales force for IV cardiovascular products (IPO use of proceeds). Since 2024 it has been evaluating licensing, joint ventures or other partnerships for this portfolio; defining this "go-forward commercialisation strategy" remains a key 2026 priority (H1 2026 release).

Revenue model

Revenue streamDescriptionFY2025 (EUR K)Share of FY2025 revenue
RoyaltiesSales-based royalties/profit share from Maxigesic IV, Sotalol IV, Podofilox Gel5,64978.4%
MilestonesUpfronts, regulatory and commercial milestones from out-licensing1,35318.8%
Product salesDirect supply of TXA RTU to partner (first in 2025)2052.8%
Total revenue—7,207100%
Other operating incomeGrants, Belgian R&D tax credits, other operational items (outside revenue)1,626—

Source: Hyloris Consolidated Results 2025 (26 March 2026). The mix is therefore licensing/royalty-dominated (~97% of revenue) with a nascent product-supply component; there is no subscription or service revenue of note (historically small IP/regulatory service income to partners was reported in FY2022).

Value-chain position, customers and end-markets

Hyloris sits between molecule owners/academic inventors and commercial pharma companies: it adds formulation IP, regulatory dossiers and clinical bridging data, then hands off to partners who own sales, distribution and often manufacturing supply. Its direct customers are therefore pharmaceutical licensees; ultimate end-users are hospitals (IV analgesia, IV cardiovascular, IV hemostasis, IV PPI), specialists (cardiology, urology, gynaecology, dermatology, ADHD/paediatrics), dentists (XTRAZA, EU only now), and, via HY-095, the veterinary (equine) market.

End-markets served: hospital acute pain (non-opioid analgesia), cardiovascular (atrial fibrillation, heart failure, acute coronary syndrome), infectious disease (herpes viruses, HPV warts, vulvovaginal infections, skin infections), haemostasis, gastroenterology (acid-related disorders), CNS (ADHD), urology (IC/BPS), haematology (iron deficiency anaemia), rare diseases (Wilson's disease, rare inherited skin disorder, hypophosphatemia), oncology (AML adjunct), neglected tropical disease (human African trypanosomiasis), and animal health.

Independent characterisation

Hyloris is best understood as a micro-cap, pre-profit, royalty-aggregation development company rather than an operating pharma business. Its 30+ asset count is broad relative to its ~54 staff and ~EUR 15–16M annual operating expense base, which implies thin resourcing per program and heavy reliance on partners and CMOs; this is visible in repeated CMO-driven delays (Metolazone IV, Valacyclovir CRL, Aspirin IV API sourcing, Suramin IV). Its royalty base is real but small and concentrated in three to four products. Equity value is largely a function of (i) US launch trajectory of Combogesic IV and Sotalol IV, (ii) out-licensing of the cardiovascular portfolio (Dofetilide IV, Aspirin IV, HY-074, Metolazone IV, Milrinone ER), and (iii) binary optionality in NCE assets (HY-094, Suramin IV PRV). Governance history (FSMA warning, trading suspension, restatement, auditor qualifications, and an authorities' site visit in October 2026) materially affects its cost of capital.

Strategy

Stated strategy themes (latest releases)

Reinvent existing medicines plus "smart NCEs": leverage 505(b)(2)-type pathways for de-risked development; selectively add NCEs with clinical validation (HY-094, Suramin IV, Methanobactin).

Development discipline: target average development cost <EUR 7M per product and time-to-market ≤7 years (selection criteria reiterated FY2024 and H1 2026).

Three-tier portfolio management (2026): Core Drivers (predictable, capital-efficient near/medium-term value, including commercialised products), Mavericks (high-potential, clinically supported), Promising Seeds (earlier-stage optionality). Pruning of sub-scale programs (HY-075, HY-091, XTRAZA US).

Partner-led commercialisation: capture a significant share of partner net margin; partner near submission; prefer profit participation over upfronts.

US cardiovascular route-to-market: define go-forward strategy (licensing, JV or other partnership) — the single most important open strategic decision.

Governance: "disciplined execution and good governance" is now explicit in outlook language (H1 2026).

Strategic initiatives — last 24 months

InitiativeDateDescription
30-asset portfolio targetAchieved Dec 2025Six new candidates added in 2025 (Pantoprazole IV RTU, Ondansetron ER, HY-094, Suramin IV, Methanobactin, HY-098)
Eight out-licensing deals in 20252,025Valacyclovir (AFT, QliniQ), XTRAZA (Colonis, AFT, Huons), TXA RTU (Orion), Atomoxetine (Rosemont), HY-094 China (Grand Life Sciences)
Governance reinforcementJul 2024–Nov 2025Communication policy (Aug 2024), external governance review, written compliance policies, board approval flows for regulated communications, Product Selection Committee
10-year strategic business planBoard-approved Dec 2025; updated 2026Reflects revised commercial timing and R&D/G&A spend (H1 2026 release)
Portfolio reviewH1 2026Discontinued HY-075, HY-091, XTRAZA US Phase 3
Euronext Securities CSD migration14 Oct 2026First Belgium-headquartered issuer to adopt Euronext Securities' new European CSD model (non-regulated release)
ESOP Warrant Plan 2026Mar 2026250,000 warrants for retention/alignment
Sustainability2022 onwardESG objectives in Annual Report 2022; ESG chapter in Annual Reports 2024/2025; LégiaPark HQ move framed around sustainability and employee well-being

Cost programs with quantified targets: none publicly announced beyond R&D phasing flexibility.

Management guidance and medium-term targets

Remainder of 2026 (H1 2026 release): regulatory submissions for Aspirin IV and Dofetilide IV in H2 2026; advance Alenura (End-of-Phase 2), HY-094 (Phase 3), Metolazone IV, Milrinone ER; define US cardiovascular strategy.

Earlier guidance (FY2024 release): up to nine product filings in 2025–2026 (Valacyclovir ex-US, Dofetilide IV, Atomoxetine, Aspirin IV, XTRAZA, Phosphate oral liquid, Metolazone IV, HY-074, Ondansetron ER). By October 2026, Valacyclovir (US, CRL) and Atomoxetine (US) have been filed; XTRAZA US is discontinued; Dofetilide and Aspirin slipped to H2 2026.

Financial targets: no quantified revenue or profitability guidance issued. Analysts (two covering, per Simply Wall St) had forecast break-even around 2026–2027 — not company guidance.

Products & Services

Organised per the company's 2026 Strategic Focus Groups (company product portfolio page, accessed October 2026; FY2025 and H1 2026 releases). Pricing models for individual products are not publicly disclosed; Hyloris earns royalties/profit shares/milestones from partners.

Core Drivers — commercialised products

ProductTypeDescription & key specsTarget customer / indicationPartner(s)Status / yearIP
Maxigesic® IV (Combogesic® IV in US)Reformulation (fixed-dose combo)IV paracetamol 1,000 mg + ibuprofen 300 mg; non-opioidHospital acute/post-operative pain and feverAFT Pharmaceuticals (worldwide co-development partner; Hyloris receives substantial minority share of AFT's margin); Hikma (US); Chengdu Tongde (China, Jul 2026); MIKASASEIYAKU (Japan, Sep 2026); Halex Istar (Brazil); nine-country European partner (2023)Licensed >100 countries, approved >50, marketed >30; EU launch 2021; FDA approval Oct 2023; US launch Feb 2024; CMS permanent J-code effective 1 Oct 2024US patents expiring Jul 2035–Aug 2036 (formulation) and Jun 2039 (manufacturing); additional EU patents granted 2025
Sotalol IVReformulationIV formulation of established antiarrhythmic enabling IV loading, potentially reducing initiation hospitalisation to ~1 dayHospital cardiology: AF/flutter rhythm maintenance; life-threatening ventricular arrhythmiasAltaThera (US commercialisation; license terminated but perpetual survival per Sept 2024 arbitration, royalties continue)FDA-approved, US commercialFormulation patents referenced through 2034
Podofilox Gel 0.5%High-barrier genericFirst US generic of Condylox GelExternal genital/perianal warts (HPV)Padagis USFDA ANDA approval Dec 2023; launched Dec 2023; stock-out Q4 2025; back on market Q2 2026Belgian manufacturing-process patent
Tranexamic Acid IV RTUHigh-barrier generic (US) / value-added (EU)Ready-to-use 10 mg/mL, 100 mL vials; no reconstitution/dilutionHospital haemostasis (labelled for haemophilia dental extraction; widely used for bleeding)Avenacy (US, profit share); Orion (key European markets, Oct 2025); South Korean distributor terminatedFDA ANDA approval Jun 2025; US and Switzerland launch H1 2026; EU registrations ongoingUS patent to 2 Dec 2039; BE patent to 17 Jun 2039

Core Drivers — late-stage pipeline

ProductTypeDescriptionIndicationPartner(s)Status (Oct 2026)IP
Valacyclovir Oral Suspension (ex HY-029)ReformulationTaste-masked, room-temperature-stable powder for suspensionHerpes zoster, cold sores, genital herpes, chickenpox (paediatric/dysphagia)Rosemont (US), AFT (Canada, Australia, NZ), QliniQ (Netherlands); rights also in major EU markets, Mexico, China, South Korea, GCCUS NDA filed Dec 2024; FDA CRL (Feb 2026) on Greek CDMO inspection, no product-specific deficiencies; second source being qualified; launch may slip into 2027; EU procedures ongoingUS patents 2035–2036; pending to 2045
Atomoxetine Oral LiquidReformulationTaste-masked oral solution for weight-based titrationADHD (paediatric)Rosemont (US, Dec 2025); Canada licensee (2023); AFT (Australia/NZ, profit share)Positive US study Jul 2025; NDA filed early 2026 by Rosemont (regulatory milestone recognised H1 2026); EU study enrolment completed Q1 2026Protection potentially to 2044
Dofetilide IVReformulationFirst IV dofetilide; IV loading could cut ≥3-day hospital initiation to ~1 dayAF/atrial flutterUS partner not yet announcedPositive pivotal (Mar 2025); FDA meeting Feb 2026 confirmed strategy; submission slipped from Q2 2026 to H2 2026Granted patents 2039–2043
Aspirin IVReformulationIV acetylsalicylic acid; faster onset vs oralACS / emergency cardiac eventsNot yet partneredPositive pivotal (Nov 2025); FDA alignment; US submission planned H2 2026; EU submissions envisagedUS patents 2038–2039
HY-074ReformulationIV formulation of a widely used oral antiplateletACSNot yet partneredRegistration batches produced; pivotal trial planned 2026Applications, expiry 2043–2044
Metolazone IVReformulationFirst injectable metolazone (lyophilised)Acute decompensated heart failure / oedemaNot yet partneredRegistration batches initiated after CMO delays; clinical completion anticipated 2026Applications, expiry 2044
Pantoprazole IV RTUReformulationDirectly injectable, storage-stable liquid PPI replacing lyophilised vialsGERD with erosive oesophagitis, hypersecretory conditions (hospital)Orion (EU, UK, Switzerland, Norway; Jan 2026; upfront received H1 2026)Formulation/registration batches in preparation; launch targeted 2028Applications, expiry 2045
Phosphate Oral Liquid (HY-088)ReformulationStandardised ready-to-use oral phosphateHypophosphatemiaQliniQ retains NL/ME/developing-country rightsRegistration batches complete; first European filing planned late H1 2026 (completion not confirmed in H1 2026 release)Applications, expiry 2045–2046
Ondansetron ERReformulationOnce-daily bimodal IR/ER oral ondansetronCINV, RINV, PONVIn-licensed from RedHill Biopharma (rights ex-North America)Late-stage; market entry targeted 2028 (FY2024 release)Confidential
XTRAZA® (TXA oromucosal solution, ex HY-004)RepurposingTranexamic acid oral rinseDental bleeding in anticoagulated patientsColonis (UK), AFT (Canada, Australia, NZ, South Korea, Singapore, Hong Kong), Huons (South Korea)US Phase 3 discontinued in 2026 despite IDMC recommendation to continue (IRR below target); scope reduced to EUUS patents to 2039
Fusidic Acid cream 2%High-barrier genericGeneric of Fucidin creamBacterial skin infections—Canadian submission expected 2026None assumed

Mavericks — high-potential, clinically supported

ProductTypeDescriptionIndicationPartner(s)StatusIP / designations
HY-094 (IV Iron, NCE)NCENext-generation IV iron with potential single-infusion dosingIron deficiency anaemiaCo-developed with AFT (global); Grand Life Sciences Group (China license, Oct 2025)Phase 2b complete; IND clearance for Phase 3 obtained H1 2026Exclusive global human-use license; patent applications
Milrinone ERRepurposingTwice-daily oral ER milrinoneRight heart failure in LVAD patientsAPI (cardiovascular development partner — royalty arrangements disclosed)Human Phase 1 PK started H1 2026Priority application 2025 (expiry 2046 if granted); FDA Orphan Drug Designation
Miconazole DB (NCE)NCE/combinationDual-action vaginal cream (miconazole + domiphen bromide)VVC and bacterial vaginosisFHP BV / Purna Female HealthcarePhase 2 dose-finding in VVC complete; exploratory BV (Gardnerella) trial in preparationIP to 2038, 2044, 2045
Suramin IV (NCE in US)NCE (first FDA approval of suramin)Standardised IV suraminT.b. rhodesiense human African trypanosomiasis; potential follow-on autism spectrum disorderKuvatris Therapeutics (Hyloris: just under 20% equity, slightly >50% of PRV net proceeds, sales royalties)Phase 3 (Africa) delayed by manufacturer issues; ASD Phase 2 completed (by partner)FDA Orphan Drug Designation; tropical disease PRV eligibility
Alenura™RepurposingReady-to-use intravesical alkalinised lidocaine + heparinIC/BPS acute pain flaresVaneltixPhase 2 (Alenura-111, 4-arm, US/Canada) enrolment completed H1 2026; End-of-Phase 2 meeting targeted H2 2026Patents to 2038

Promising Seeds — early stage

ProductTypeDescriptionIndicationPartner(s)Status
HY-083NCE trackIntranasal TRPV1 agonist sprayIdiopathic rhinitisWalloon Region grant (EUR 1M)NCE candidates synthesised; potency in assays
HY-095Reformulation (veterinary)Long-acting injectable PPIEquine Gastric Ulcer SyndromeExternal formulation partnerFirst horse prototype testing 2025; further testing 2026
HY-098RepurposingTopical form of an established systemic drugRare inherited inflammatory skin disorderWake Forest University School of Medicine (option)Exploratory trial may start 2026
HY-089 (also referenced as HY-090 in earlier releases)RepurposingLocally acting oral solutionBurning mouth syndromeAFT (equal partnership)Two pre-prototypes
HY-086 (PTX-252)NCEChelating adjunct to chemotherapyAML (plus SCLC exploratory)Pleco TherapeuticsFormulation complete; Phase 1 preparation delayed (CTA); FDA ODD in AML; financing delay led to receivable impairment H1 2026
HY-106 (Methanobactin, ARBM-101)NCECopper-selective injectable chelator, potentially intermittent dosingWilson's disease (EU/Turkey rights)ArborMed (USD 2M upfront paid; ArborMed buy-back option pre-Phase 3)First-in-human (healthy volunteers) planned 2026

Discontinued / divested programs (recent)

ProgramDateReason
HY-075 (oral liquid CV)H1 2026Portfolio review / capital allocation (development previously paused pending partnering)
HY-091 (vulvar lichen sclerosus, with AFT)H1 2026Portfolio review
XTRAZA US Phase 3 and US development2,026Recruitment rate and per-patient cost implied sub-target IRR
HY-038 (generic)Divested Dec 2022/Jan 2023 to QliniQNon-core; transaction later restated as non-monetary exchange

Financial Narrative

Basis: IFRS consolidated statements. FY2022 shown as restated (14 March 2024 restatement reversing EUR 1.0M HY-038 revenue). FY2021–FY2022 from FY2022 results release; FY2023–FY2024 from FY2024 results release; FY2025 from FY2025 results release. "Derived" items are analyst calculations from reported figures. Note that later releases occasionally reclassify prior-year items (e.g., FY2024 operating cash flow shown as -6,703 in the FY2024 release and -6,903 in the FY2025 release); the original-year figure is used unless stated.

Income statement

EPS notes: FY2022 restated EPS (-0.435) and FY2024/FY2025 EPS (-0.23) are as reported; FY2021 (-0.45) and FY2023 (-0.55) are derived from net loss over period-end share count (25.83M and 28.00M respectively) and should be treated as approximations. FY2021 "other operating expenses" of EUR 5.77M (largely one-off, linked to the Alter Pharma renegotiation era) depressed FY2021 EBIT; FY2021 SG&A presentation differs between tables in the FY2022 release.

Margins and growth

Revenue CAGR FY2021–FY2025 (derived): 23.5% (EUR 3.10M → EUR 7.21M). Using total operating income: 26.2%.

Commentary. The P&L shows three phases. (1) FY2021–FY2023: rising R&D investment (EUR 5.1M → EUR 14.4M, including a USD 2M Vaneltix R&D funding expensed in 2023) against stagnant, milestone-driven revenue, pushing net losses to a peak of EUR 15.4M. (2) FY2024 inflection: revenue quadrupled to EUR 8.5M on the Combogesic IV US launch milestone, first meaningful royalties (Maxigesic IV, Podofilox) and Valacyclovir upfront/regulatory payments, while R&D phasing fell 29%; net loss more than halved to EUR 6.3M despite EUR 2.2M of legal/forensic costs. (3) FY2025 consolidation: royalties +15% but milestone normalisation cut revenue 15%; G&A fell on lower legal costs while R&D rose 10% on headcount; net loss flat at EUR 6.3M. Gross margins are structurally ~95% because revenue is royalty-based; the relevant profitability lever is operating expense versus royalty scale. H1 2026 extended the improvement (net loss EUR 1.9M vs EUR 3.6M), helped by milestone income and a 16% R&D reduction from project phasing — partly timing rather than structural.

Balance sheet

Notes: The company states it has "no financial debt"; borrowings are IFRS 16 lease liabilities (office, lab equipment, cars). FY2021 other financial liabilities included shareholder loans repaid in 2022 (EUR 9.28M including interest). FY2022 equity and assets are restated (-EUR 1.0M). At 30 June 2026: cash EUR 8,735k, equity EUR 24,943k (H1 2026 release).

Commentary. Hyloris has funded EUR ~65M of cumulative losses since the 2020 IPO from IPO proceeds and the 2022 EUR 15M placement, without debt. Cash has declined every year (EUR 64.4M at end-2020 → EUR 13.8M at end-2025 → EUR 8.7M at mid-2026). Intangibles rose in FY2025 on in-licensing (including the USD 2M ArborMed upfront). Equity-accounted investees reflect FHP BV and, from 2025, Kuvatris.

Cash flow: notes and sources

Notes: FY2023 net change in cash was cushioned by EUR 10.0M of matured financial investments. FY2025 investing outflow of EUR 2.1M mainly reflects the Kuvatris equity investment (EUR 1.9M). H1 2026 cash decline: EUR 5.0M in six months.

Ratios

ROIC: negative and not meaningful (negative NOPAT; one vendor computes -45.7% TTM). Net debt/EBITDA and interest coverage: not meaningful (net cash, negative EBITDA, negligible interest). Cash conversion cycle: not meaningful/not publicly disclosed (royalty model, inventory EUR 52k at end-2025).

Ratio commentary. Returns are deeply negative but improving from the FY2023 trough. Liquidity ratios appear comfortable on a current-ratio basis but mask the absolute cash constraint: at the H1 2026 burn rate (~EUR 10M annualised before new milestones), end-June 2026 cash of EUR 8.7M covers less than a year without additional partnering inflows, which is why management cites expected out-licensing proceeds, R&D phasing flexibility and a CEO comfort letter.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Revenue by Segment

MetricFY2023FY2024FY2025

Royalties (EUR K)

—4,9015,649

Milestones (EUR K)

—3,5571,353

Product sales (EUR K)

—0205

Total revenue (EUR K)

2,0878,4587,207

Other operating income (EUR K)

2,1271,5841,626

Total operating income (EUR K)

4,21410,0438,832

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Segment Margins & Growth (%) and Revenue by Segment (%)

MetricFY2024FY2025

Royalties YoY growth (%)

—15

Milestones YoY growth (%)

—-62

Royalties share of revenue (%)

57.978.4

Milestones share of revenue (%)

42.118.8

Product sales share of revenue (%)

02.8

Revenue by Segment (Half-Yearly)

MetricH1 2025H1 2026

Revenue (EUR K)

3,0184,696

Royalties (EUR K, H1 2025 rounded)

2,9002,917

Other operating income (EUR K)

765877

Total operating income (EUR K)

3,7845,573

Entity / Investee Details

Entity / investeeNatureRelevance

Hyloris Pharmaceuticals SA

Parent, Liège

Listed holding/operating company

Subsidiaries

Not detailed in sources reviewed (consolidated "Group" referenced)

Not publicly disclosed in reviewed documents

FHP BV

Equity-accounted joint venture with Maatschap Purna and others

Miconazole-Domiphen Bromide program; carrying value EUR 2.7M (FY2024), impairment EUR 972k in 2024 reversed in 2025

Kuvatris Therapeutics Inc.

Equity-accounted investee (just under 20%)

Suramin IV; USD 1.6M equity investment

Pleco Therapeutics BV

Other financial asset (loan converted to shares, EUR 1.0M)

PTX-252 (HY-086); EUR 474k receivable impairment in H1 2026

Income Statement and Per-Share Data

MetricFY2021FY2022FY2023FY2024FY2025

Revenue (EUR K)

3,0961,9512,0878,4587,207

Other operating income (EUR K)

3893152,1271,5841,626

Total operating income (EUR K)

3,4852,2664,21410,0438,832

Cost of sales (EUR K)

-107-94-93-227-379

Gross profit (EUR K, derived)

2,9891,8571,9948,2316,828

R&D expenses (EUR K)

-5,056-10,151-14,421-10,265-11,281

G&A expenses (EUR K)

-2,900-3,517-5,546-5,627-4,882

Operating profit / EBIT (EUR K)

-10,541-11,638-15,993-7,130-6,808

D&A and impairments (EUR K)

137196349648919

EBITDA (EUR K, derived)

-10,404-11,442-15,644-6,482-5,889

Pre-tax income (EUR K)

-11,282-11,766-15,380-6,342-6,707

Net income (EUR K)

-11,579-11,770-15,380-6,342-6,334

EPS basic (EUR)

-0.45-0.435-0.55-0.23-0.23

EPS diluted (EUR)

-0.45-0.435-0.55-0.23-0.23

Dividends per share (EUR)

00000

Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Revenue YoY growth (%)

—-37.07.0305.3-14.8

Gross margin (%)

96.595.295.597.394.7

Operating margin (%)

-340.5-596.5-766.3-84.3-94.5

EBITDA margin (%)

-336.0-586.5-749.6-76.6-81.7

Net margin (%)

-374.0-603.3-737.0-75.0-87.9

R&D as % of revenue (%)

163.3520.3691.0121.4156.5

Balance Sheet

MetricFY2021FY2022FY2023FY2024FY2025

Total assets (EUR K)

63,44460,86447,68141,33533,357

Cash and cash equivalents (EUR K)

50,01243,45730,40623,59413,775

Lease borrowings short-term (EUR K)

65138241326364

Lease borrowings long-term (EUR K)

1097471,5101,4891,246

Total lease borrowings (EUR K)

1748851,7511,8151,610

Other financial liabilities current (EUR K)

11,8153,2123,2003,0000

Net debt (lease borrowings minus cash, EUR K)

-49,838-42,572-28,655-21,779-12,165

Total equity (EUR K)

48,05654,04539,06932,14326,475

Goodwill (EUR K)

00000

Intangible assets (EUR K)

2,9443,6073,8283,8385,689

Equity-accounted investees (EUR K)

4,0793,9483,8012,7482,543

Working capital (EUR K, derived)

38,98144,02928,54922,54514,825

Cash Flow

MetricFY2021FY2022FY2023FY2024FY2025

Operating cash flow (EUR K)

-11,250-13,154-12,808-6,703-6,994

Capex PP&E (EUR K)

-107-101-298-29-4

Capex intangibles (EUR K)

-954-638-452-268-625

Free cash flow (EUR K, derived)

-12,311-13,893-13,558-7,000-7,623

Equity raised net (EUR K)

017,169000

Dividends paid (EUR K)

00000

Share buybacks (EUR K)

00000

Net change in cash (EUR K)

-14,387-6,555-3,051-6,812-9,550

Returns & Leverage Ratios (%) and Financial Ratios (x)

MetricFY2021FY2022FY2023FY2024FY2025

ROE (%, on average equity; FY2021 on year-end)

-24.1-23.1-33.0-17.8-21.6

ROA (%, on average assets; FY2021 on year-end)

-18.3-18.9-28.3-14.2-17.0

Current ratio (x)

3.608.635.224.153.89

Debt to equity (lease debt, x)

0.0040.0160.0450.0560.061

Asset turnover (x)

0.050.030.040.190.19

Revenue by Region

MetricFY2023FY2024FY2025

Total revenue (EUR K)

2,0878,4587,207

Products

ProductPrincipal revenue geographiesEvidence

Sotalol IV

United States only

AltaThera US commercialisation

Podofilox Gel

United States only

Padagis; US-manufactured

TXA RTU

United States (Avenacy, launched H1 2026), Switzerland (launched H1 2026), Europe (Orion, registrations ongoing)

FY2025 and H1 2026 releases

Maxigesic IV

South Korea (historically the highest-selling country per FY2024 release), Europe (launched from 2021), United States (Hikma since Feb 2024; royalties subject to cumulative sales threshold per FY2024 release), Canada, Brazil, Asia; China and Japan pending registration

FY2024/FY2025 releases; Jul and Sep 2026 releases

Data Point Details

Data pointValueSource

Last close (16 Oct 2026)

EUR 4.28 (+4.65% on day; intraday range 3.69–4.29)

Company share page

Market capitalisation

EUR 119.8M

Company share page

Performance year-to-date 2026

-40.2%

Company share page

Performance over last full year

-29.73%

Company share page

Performance 1 month

-3.54%

Company share page

Since IPO (EUR 10.75, Jun 2020)

-60.2% (derived)

Euronext IPO release; derived

52-week range (as of May 2026)

EUR 4.51–8.40 (since breached to 3.69 low in Oct 2026)

Investing.com

Average daily volume (3m, May 2026)

~7,150 shares

Investing.com

Share Count (millions) and Capital Markets Data

MetricFY2021FY2022FY2023FY2024FY2025

Shares outstanding year-end (millions)

25.8328.0028.0028.0028.00

Share capital (EUR K)

129140140140140

Valuation Multiples

MultipleHylorisBasis

P/E

Not meaningful (loss-making; EPS FY2025 -0.23)

—

EV (EUR Mn)

~112.6

Market cap 119.8 less cash 8.7 plus leases ~1.5 (30 Jun 2026)

EV/Sales FY2025

~15.6x

Revenue EUR 7.21M

EV/Sales TTM (H2 2025 + H1 2026)

~12.7x

TTM revenue EUR 8.89M (derived)

EV/EBITDA

Not meaningful (negative EBITDA ≈ -EUR 5.9M FY2025)

—

P/B

~4.8x

Equity EUR 24.9M (30 Jun 2026)

Peer reference

Eton Pharmaceuticals ~16x TTM sales (market cap USD 1.70B; TTM revenue USD 105.6M, StockAnalysis, Aug 2026)

Profitable, growing peer

Analyst Ratings & Targets

BrokerAnalystRating (date per company site)

Degroof Petercam

David Seynnaeve

Buy (21 Mar 2025)

Kepler Cheuvreux

Christophe Dombu

Buy (21 Mar 2025)

KBC Securities

Jacob Mekhael

Hold (21 Mar 2025)

Van Lanschot Kempen

Suzanne van Voorthuizen

Under review (21 Mar 2025)

Analyst Conclusions

Management guidance (H1 2026 release)

Submissions for Aspirin IV and Dofetilide IV in H2 2026; End-of-Phase 2 for Alenura in H2 2026; HY-094 Phase 3 advancement; Metolazone IV, Milrinone ER progress; definition of the US cardiovascular commercialisation strategy (licensing or other partnerships); continued disciplined execution and governance. No quantitative financial guidance.

Consensus expectations

Two to four sell-side analysts; aggregators show break-even expectations around 2026–2027 and steep revenue ramps (MarketScreener FY2027E EUR 65.4M), implying large licensing milestones — high uncertainty and not company-endorsed.

Bull case

  1. Royalty compounding plus new territories: Maxigesic/Combogesic IV (US promotion from late Q2 2026, China via Tongde, Japan via Mikasa) and TXA RTU (US, Switzerland, Europe via Orion) could lift recurring revenue materially above FY2025's EUR 5.9M.

  2. CV portfolio monetisation: two positive pivotal CV assets (Dofetilide IV, Aspirin IV) with FDA alignment provide a credible package for a US licensing deal with upfront payments that would solve the funding question.

  3. Asymmetric NCE optionality: a Suramin IV PRV (Hyloris >50% of net proceeds) or HY-094 Phase 3 success could each be worth a large fraction of the EUR ~120M market cap.

Bear case

  1. Funding gap: EUR 8.7M cash against ~EUR 10M annual burn means a near-term dilutive raise or reliance on the CEO comfort letter unless partnering inflows arrive on time.

  2. Governance/legal overhang: the October 2026 authorities' visit revives the 2024 QliniQ affair; possible sanctions, management distraction, and a persistent valuation discount.

  3. Execution slippage: repeated delays (Dofetilide filing, Valacyclovir CRL, Metolazone, Suramin) and program cuts (XTRAZA US) suggest timelines and consensus revenue ramps are too optimistic.

Key catalysts and monitorables (next 12 months)

CatalystExpected timing
Dofetilide IV US NDA submissionH2 2026
Aspirin IV US submission (and EU)H2 2026
US cardiovascular portfolio partnering decision/deal2026–2027 (no date)
Alenura End-of-Phase 2 FDA meetingH2 2026
Outcome of authorities' investigation; any FSMA actionUnknown
Atomoxetine Oral Liquid FDA action (Rosemont)2026–2027 (PDUFA not disclosed)
Valacyclovir resubmission after CDMO remediation/second sourceInto 2027
HY-088 European filing confirmationOverdue vs late H1 2026 plan
Combogesic IV US royalty trajectory and Hikma promotionQuarterly via partner disclosures
FY2026 results25 Mar 2027
Financing announcement (equity, partnership, use of CEO support)Any time

Analyst verdict

Hyloris has largely delivered on the operational promise of its model: it has turned a reformulation pipeline into four partnered commercial products, a royalty line that grew 15% in FY2025, two positive pivotal cardiovascular assets with FDA alignment, and an unusually active licensing cadence that now reaches China and Japan for Maxigesic IV. H1 2026 showed the best half-year loss since the 2020 IPO, and the asset-light structure keeps gross margins near 95% and the balance sheet debt-free.

The investment case, however, is constrained by three factors that dominate the fundamentals. First, liquidity: EUR 8.7M of cash at mid-2026 against an underlying burn near EUR 10M per year makes the next twelve months a race between partnering inflows and dilution; the explicit reliance on a CEO comfort letter in the going-concern assessment is a telling signal. Second, governance: the 2024 FSMA warning, trading suspension, restatement, serial audit qualifications and now an authorities' document request in October 2026 impose a credibility discount that no amount of pipeline news has yet offset, as reflected in a share price 60% below the IPO and 40% down year-to-date. Third, scale: royalties of EUR 5.6M remain far below an operating cost base of ~EUR 15M, so profitability depends on lumpy milestones and an as-yet-unannounced US cardiovascular deal.

At ~EUR 113M EV (~13x TTM revenue), the market is pricing some, but not full, success. The stock is best characterised as a high-risk, catalyst-driven special situation: a credible US cardiovascular licensing deal with meaningful upfront cash, clean resolution of the regulatory inquiry, or Suramin PRV progress could re-rate it sharply, while a discounted equity raise or adverse regulatory outcome would likely reset it lower. Position sizing should reflect binary risk; the verdict is speculative, event-driven — monitor funding and governance resolution before conviction.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenurePrior rolesEducationAge

Stijn Van Rompay (via SVR Management BV)

CEO & co-founder

Co-founder 2012; CEO; co-CEO Jul 2024–Nov 2025; sole CEO since 19 Nov 2025

Co-founder/CEO Alter Pharma; co-CEO Uteron Pharma; CFO then CEO Docpharma

Master's in Applied Economics (University of Antwerp); honorary doctorate (Long Island University)

Born 1975 per Beursgenoten (not company-verified)

Thomas Jacobsen (via Jacobsen Management BV)

Chief Business Development Officer & co-founder

Co-founder 2012; co-CEO mid-2024 to Nov 2025

Co-founder Alter Pharma; Docpharma (out-licensing); Alternova

Master's in Pharmacy (University of Copenhagen); business degree (Copenhagen Business School)

Not publicly disclosed (vendors cite 1974/1975)

Christophe Maréchal (via CMM&C SRL)

CFO

Since Dec 2024

Senior finance roles at Orange, AGC, Mithra Pharmaceuticals; >30 years experience

MBA/Commercial Engineering (University of Liège); econometrics studies (Tilburg)

—

Dr. Dietmar Aichhorn

COO

—

Sandoz, Mylan, Innovacell, ViraTherapeutics, Polpharma Biologics (head clinical development roles)

Master's in Chemistry (Kepler University Linz); doctorate (Vienna University of Economics and Business)

—

Ann De Jaeger (via Impact WITH Empathy BV)

Chief Legal Officer & General Secretary to the Board

Since Aug 2025

Tate & Lyle, Barco, Alpro, Danone, What's Cooking Group

Master of Law (Ghent); business law (Antwerp); IMD/MIT/Vlerick; certified board director

—

“—” = not publicly disclosed.

Board of Directors

NameRoleIndependenceNotes

Vincent Van Dessel (Sybefica Invest SRL)

Chairman since Jun 2026

Independent

Former Chairman & CEO Euronext Brussels; Chairman of VFB (Belgian retail investors' federation) since Jan 2025

Stefan Yee

Non-executive director (Chairman until Jun 2026; website still lists "Chairman")

Not stated as independent

PE investor (PE Group/Arteva Capital); ex-KPMG, Linklaters; former director of Docpharma, Uteron

Leon Van Rompay

Non-executive director

Non-independent

Founder/CEO Docpharma; former Zambon board member; >40 years pharma

Dr. Mélanie Mestdagt (Biofinance Consulting BV)

Non-executive director since Jun 2025 (3-year term)

Independent

CEO EyeD Pharma and UniD Manufacturing; VP BioWin

Dr. Revital Rattenbach (IRYL Partners SAS)

Non-executive director; Chair of Product Selection Committee

Independent

Founding CEO 4P-Pharma; board member Biosenic

Stijn Van Rompay

Executive director (CEO)

Executive

—

Thomas Jacobsen

Board membership as of 2026 not confirmed in company sources (listed as board member by data vendors)

Executive

—

Board & Management Changes

DateChangeContext

8 Jul 2024

Thomas Jacobsen appointed co-CEO; CFO Jean-Luc Vandebroek and CLO Koenraad Van der Elst to leave

Board decisions following forensic review of QliniQ transactions and FSMA warning

9 Dec 2024

Christophe Maréchal appointed CFO

Replacement of departed CFO

Jun 2025

Marc Foidart resigns; Biofinance Consulting (Mestdagt) appointed

AGM board renewal

Aug 2025

Ann De Jaeger appointed CLO

Fills CLO vacancy

19 Nov 2025

Stijn Van Rompay sole CEO; Jacobsen returns to CBDO

External governance review; the 2024 plan to transition to an independent CEO was not pursued

9 Jun 2026

Vincent Van Dessel appointed Chairman

Succeeds Stefan Yee as Chair

Major Shareholders

HolderShares / stakeSource & dateComment

Stijn Van Rompay (CEO)

~10.27M shares (~36.7%)

Simply Wall St (May 2025)

Conflicts with Beursgenoten (7,743,067 shares; 27.65%) and last FSMA notification (26.42%, Jul 2020) — discrepancy noted; company's own Mar 2026 chart not machine-readable

Thomas Jacobsen (CBDO)

~3.86M shares (~13.8%)

Simply Wall St (May 2025)

FSMA notification Jun 2020: 13.43%

Bart Versluys (Scorpiaux BV, Versluys Bouwgroep NV)

2,119,774 (7.57%)

Transparency notification, threshold crossed 9 Jan 2026

Only recent formal notification

Nick Reunbrouck

1,610,184 (6.29% at the time)

FSMA notification Jun 2020

Possibly outdated

Pieter Van Rompay

915,000 (3.58% at the time)

FSMA notification Jun 2020

Possibly outdated

Saffelberg Investments NV

~3%

Transparency notification 29 Jun 2022; vendor 3.07%

—

Edward Maloney

~1.6%

Simply Wall St (older snapshot)

—

Mandarine Gestion

77,000 (0.29%)

Simply Wall St (older snapshot)

Institutional

Degroof Petercam Asset Management

15,000 (0.05%)

Simply Wall St (May 2025)

Institutional

Dimensional Fund Advisors

5,164 (0.02%)

Simply Wall St (May 2025)

Institutional

Competitive Landscape

Competitors by Segment

AreaCompetitor(s)Relationship to Hyloris

Value-added medicines / reformulation platforms

Eton Pharmaceuticals (US, paediatric/rare reformulations); Azurity Pharmaceuticals (US, private, oral liquids); AFT Pharmaceuticals (also partner)

Compete for in-licensing deals and 505(b)(2) niches

Non-opioid hospital analgesia

Pacira BioSciences (EXPAREL); Heron Therapeutics (ZYNRELEF); B. Braun and Fresenius Kabi (IV paracetamol); Vertex (oral non-opioid suzetrigine)

Compete with Maxigesic/Combogesic IV for post-operative protocols

Antiarrhythmics

Pfizer (Tikosyn oral dofetilide) and generic dofetilide makers; amiodarone IV suppliers

Dofetilide IV/Sotalol IV positioned against oral initiation and IV amiodarone

IV iron

CSL Vifor (ferric carboxymaltose), Pharmacosmos (ferric derisomaltose), Daiichi Sankyo/American Regent (US)

HY-094 must differentiate on single-dose tolerability

IV PPI

Pfizer (Protonix IV) and lyophilised pantoprazole generics

Pantoprazole IV RTU targets convenience share

Generic injectables (TXA)

Fresenius Kabi, Hikma, Exela and others in TXA IV

TXA RTU competes on ready-to-use format

ADHD liquids

Tris Pharma and other liquid stimulant/non-stimulant suppliers

Atomoxetine Oral Liquid niche

Peer Comparison FY2025

CompanyFYRevenueRevenue growth (%)Gross margin (%)Operating/net marginR&D intensity (%)

Hyloris Pharmaceuticals

FY2025 (Dec)

EUR 7.2M

-1594.7

Operating margin -94.5%

156.5

Pacira BioSciences

FY2025 (Dec)

USD 726.4M

4

~81 (company commentary)

GAAP net income USD 7.0M (~1.0% net margin)

16.1 (R&D USD 117.3M)

Eton Pharmaceuticals

FY2025 (Dec)

USD 79.9M

105

53.5 (gross profit USD 42.7M)

Adjusted EBITDA USD 15.8M (~19.8%)

—

AFT Pharmaceuticals

FY2026 (Mar)

NZD 254.7M

2243.4

Operating margin 9.6%

3.9 (R&D NZD 9.8M)

Company Snapshot

$8.1M

Revenue

54

Employees

2012

Founded

Liège, Belgium

Headquarters

SWOT Analysis

Strengths

  • Growing royalty base: royalties rose from EUR 4.9M (FY2024) to EUR 5.6M (FY2025, +15%), with combined Maxigesic IV and Sotalol IV royalties up 98% (FY2025 release).
  • Four commercialised products following the June 2025 TXA RTU FDA approval and H1 2026 US/Swiss launch.
  • Global Maxigesic IV footprint: licensed in >100 countries, approved in >50, launched in >30; new China (Jul 2026) and Japan (Sep 2026) agreements.
  • High partnering cadence: eight out-licensing agreements in 2025 plus Orion Pantoprazole (Jan 2026).
  • Clinical execution on CV assets: positive pivotal data for Dofetilide IV (Mar 2025) and Aspirin IV (Nov 2025), with FDA alignment on both.
  • No financial debt: borrowings limited to EUR 1.6M of lease liabilities (FY2025).
  • Capital-light cost structure: operating expenses fell from EUR 20.1M (FY2023) to EUR 15.6M (FY2025).

Weaknesses

  • Persistent losses: cumulative retained losses of EUR 92.8M at end-2025; no profitable year since IPO.
  • Liquidity: cash fell to EUR 8.7M at 30 June 2026 from EUR 13.8M six months earlier.
  • Revenue concentration and lumpiness: milestones swung from EUR 3.6M (FY2024) to EUR 1.4M (FY2025).
  • CMO dependence: Valacyclovir CRL (Feb 2026) from CDMO inspection findings; repeated Metolazone IV registration-batch delays.
  • Governance track record: FY2022 restatement, 2024 trading suspension, FSMA public warning, and audit qualifications in FY2023/FY2024 and FY2025 (comparability of other operating income).
  • Negligible institutional ownership (<1%) and thin trading liquidity limit financing options.

Opportunities

  • US cardiovascular out-licensing (Dofetilide IV, Aspirin IV, HY-074, Metolazone IV, Milrinone ER) could deliver upfronts and royalties without commercial build-out.
  • Suramin IV Priority Review Voucher: Hyloris holds slightly >50% of net PRV proceeds if approved.
  • HY-094 Phase 3 with AFT and Grand Life Sciences cost sharing, addressing a USD 3B+ IV iron market.
  • Combogesic IV acceleration in the US from late Q2 2026 promotion and permanent J-code.
  • Valacyclovir and Atomoxetine US approvals via Rosemont (Atomoxetine NDA filed early 2026).
  • Pantoprazole IV RTU in a USD 450M market with Orion as EU partner and a 2028 launch target.

Threats

  • Regulatory/legal: authorities' site visit on 14 October 2026 on historical FSMA-related matters; potential sanctions or reputational damage.
  • Financing/dilution: going-concern assessment relies partly on a CEO comfort letter of up to EUR 2.5M through September 2027 (H1 2026 release); equity raise at depressed prices would be dilutive (share -40.2% YTD to 16 Oct 2026).
  • US pricing policy (340B and broader reforms) affecting hospital product economics (FY2025 release).
  • Partner execution risk: prior AltaThera arbitration; China partner turnover for Maxigesic IV.
  • Competitive pressure from established non-opioid and IV generic suppliers (Pacira, B. Braun, Fresenius Kabi) and new oral non-opioids.
  • FX: weaker USD reduced FY2025 royalties and produced FX losses (financial expenses EUR 739k).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
30 Apr 2025Annual Report 2024 published (incl. ESG chapter)Timely filing after 2024 delays
13 May 2025Valacyclovir partnerships: AFT (Canada, Australia, NZ), QliniQ (Netherlands)Ex-US commercial coverage
22 May 2025XTRAZA license with AFT (Canada, Australia, NZ, South Korea, Singapore, Hong Kong)Expanded territory (later US program cut)
3 Jun 2025FDA approval of TXA RTU ANDA (Avenacy)Fourth commercial product
10 Jun 2025AGM; board partially renewed (Foidart out, Mestdagt in)Governance refresh
23 Jun 2025Kuvatris partnership for Suramin IVPRV optionality; ~20% equity stake
17 Jul 2025Positive Atomoxetine Oral Solution clinical resultsEnabled US NDA
Aug 2025Ann De Jaeger appointed CLOLegal/compliance leadership restored
22 Aug 2025XTRAZA license with Huons (South Korea)Asia channel
25 Sep 2025H1 2025 results: royalties ~EUR 2.9M (+~30%), net loss EUR 3.6M, cash EUR 18.6MSeveral timelines pushed into 2026 (Alenura, XTRAZA data, HY-074)
12 Oct 2025Valacyclovir PDUFA date (as set)Outcome later disclosed as CRL
27 Oct 2025HY-094 China license with Grand Life SciencesPartner cost-sharing
28 Oct 2025TXA RTU partnership with Orion (Europe)Pan-European distribution
14 Nov 2025Positive Aspirin IV clinical resultsCV portfolio progress
19 Nov 2025Stijn Van Rompay appointed sole CEO; governance measuresResolves 2024 interim structure; independent-CEO plan dropped
11 Dec 2025Wake Forest exclusive license option (HY-098)Rare disease seed
29 Dec 2025Rosemont partnership for Atomoxetine (US)US commercial partner
30 Dec 2025ArborMed license (Wilson's disease, EU/Turkey), USD 2M upfrontNCE addition
Jan 2026Versluys group crosses 7.5% threshold (acquisition 9 Jan)Shareholder accumulation
19 Jan 2026Orion license for Pantoprazole IV RTU (30 European countries)Upfront received H1 2026
Early 2026Rosemont files US NDA for Atomoxetine Oral LiquidRegulatory milestone recognised
Feb 2026FDA meeting confirms Dofetilide IV regulatory strategyDe-risks filing
19 Feb 2026Update on FDA review of Valacyclovir (CRL on CDMO inspection)Launch may slip to 2027
Mar 2026ESOP Warrant Plan 2026 (250,000 warrants)Dilution/retention
26 Mar 2026FY2025 results: revenue EUR 7.2M (-15%), net loss EUR 6.3M, cash EUR 13.8MAuditor qualification on comparability of other operating income
30 Apr 2026Annual Report 2025 published–
20 May 2026Exclusive company visit (investor event)IR activity
9–10 Jun 2026AGM (48.5% of shares represented); Vincent Van Dessel appointed ChairmanGovernance
24 Jun 2026AFT obtains FDA clearance for Phase 3 of injectable iron (HY-094)Mavericks catalyst
14 Jul 2026New Maxigesic IV China license (Tongde)Replaces terminated deal
24 Sep 2026H1 2026 results: revenue +56% to EUR 4.7M, net loss EUR 1.9M, cash EUR 8.7M; program discontinuations; CEO EUR 2.5M comfort letterLiquidity focus; Dofetilide/Aspirin filings H2 2026
27 Sep 2026Maxigesic IV Japan agreement (AFT–Mikasa)New territory
14 Oct 2026Authorities visit Liège office regarding historical matters previously engaged with FSMA; CSD migration announcedRenewed governance/legal overhang
15 Oct 2026Holding statement: full cooperation, business as usualRegulated disclosure

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

5 charts
Income Statement: Revenue & Gross Profit: Revenue rose from EUR 3.1 Mn in FY2021 to EUR 7.2 Mn in FY2025.
Hyloris Pharmaceuticals SA — Income Statement: Revenue & Gross Profit
Series (EUR Mn)FY2021FY2022FY2023FY2024FY2025
Revenue3.122.18.57.2
Cost of sales-0.1-0.1-0.1-0.2-0.4
Gross profit31.928.26.8

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. Hyloris Pharmaceuticals, "Consolidated Results 2025" press release, 26 March 2026 (vfb.be mirror and hyloris.com)
  2. Hyloris Pharmaceuticals, "Consolidated 2026 Half-Year Results and Outlook", 24 September 2026 (hyloris.com)
  3. Hyloris Pharmaceuticals, "Hyloris Holding Statement – Ongoing Investigation", 15 October 2026
  4. Hyloris Pharmaceuticals, "Partner AFT Signs Exclusive Agreement with MIKASASEIYAKU for Maxigesic IV in Japan", 27 September 2026
  5. Hyloris Pharmaceuticals, "New Exclusive Licensing Agreement for Maxigesic IV in China", 14 July 2026
  6. Hyloris Pharmaceuticals, "Annual General Shareholders Meeting held", 10 June 2026
  7. Hyloris Pharmaceuticals, transparency notification disclosure (Versluys), 2 February 2026
  8. Hyloris Pharmaceuticals, "Board of Directors appoints Stijn Van Rompay as CEO", 19 November 2025
  9. Hyloris Pharmaceuticals, "Reports 2024 Results and Provides Business Outlook", 20 March 2025
  10. Hyloris Pharmaceuticals, "Update on Developments Following Completion of Forensic Independent Review", 8 July 2024
  11. Hyloris Pharmaceuticals, "Communication at the request of the FSMA on the transactions with Qliniq", 14 March 2024
  12. Hyloris Pharmaceuticals, "Full year results for 2022 & business outlook", 15 March 2023
  13. Hyloris Pharmaceuticals, H1 2025 results press release and Half Year Report 2025, 25 September 2025
  14. Hyloris website: Product Portfolio, Investors, Press Releases, The Hyloris Share pages (accessed October 2026)
  15. Euronext, "Hyloris Pharmaceuticals lists on Euronext Brussels", 29 June 2020; Eubelius IPO note
  16. FSMA issuer shareholding overview (0674494151) and manager transaction records
  17. Bolero/KBC Securities blog notes (25 Sep 2025; 26 Mar 2026)
  18. MarketScreener (calendar, consensus, news), Investing.com, MarketInOut, Simply Wall St, Beursgenoten, Morningstar profiles (third-party data, flagged where used)
  19. RTTNews, "Hyloris Pharmaceuticals SA H1 Loss Decreases", September 2026
  20. Pacira BioSciences FY2025 results (8-K, February 2026); Eton Pharmaceuticals FY2025 results (8-K, 19 March 2026); AFT Pharmaceuticals FY2026 results (NZX, 21 May 2026) and StockAnalysis financials

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.